Morgan Stanley Aslan Pharmaceuticals LTD Transaction History

Morgan Stanley

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	SELL	$0.36 - $24.24 $68 - $4,581	-189 Reduced 0.13%	150,794 $54,000
Q3 2022 Nov 14, 2022	SELL	$0.42 - $24.68 $43,666 - $2.57 Million	-103,967 Reduced 40.78%	150,983 $91,000
Q2 2022 Oct 27, 2022	SELL	$0.36 - $0.9 $87,127 - $217,819	-242,022 Reduced 48.7%	254,950 $127,000
Q2 2022 Aug 15, 2022	SELL	$0.36 - $0.9 $87,127 - $217,819	-242,022 Reduced 48.7%	254,950 $127,000
Q1 2022 Oct 27, 2022	BUY	$0.74 - $1.22 $179,096 - $295,266	242,022 Added 94.93%	496,972 $447,000
Q1 2022 May 13, 2022	BUY	$0.74 - $1.22 $182,153 - $300,306	246,153 Added 98.14%	496,972 $447,000
Q4 2021 Feb 14, 2022	BUY	$1.11 - $1.86 $12,555 - $21,038	11,311 Added 4.72%	250,819 $281,000
Q3 2021 Nov 15, 2021	BUY	$1.78 - $3.41 $426,324 - $816,722	239,508 New	239,508 $426,000

Ticker ASLN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 69,744,704
Market Cap $41.8M
Description
ASLAN Pharmaceuticals Limited, a clinical-stage immunology focused biopharmaceutical company, engages in developing various treatments to transform the lives of patients. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications; and ASLAN003, a small-m...

Get notified when there are updates to the investment portfolio of Morgan Stanley, based on Form 13F filings with the SEC.

Stay updated on Morgan Stanley with notifications on news.